Our clients operate in dual environments—life science and business—and we shape our teams around the common challenges facing these segments. Valid Insight experts draw on decades of market access, medical and relevant commercial experience.
BSc (Hons.), MB BChir, MRCOphth
Steve Bradshaw is Managing Director of Valid Insight. He has two decades’ experience in market access consulting and healthcare. He has developed price and access strategies and value communication tools for many well-known products on the market, and has moderated numerous client workshops covering many aspects of market access, pricing, tendering and contracting.
Steve’s career includes being Editor at Nature Clinical Reviews, Ophthalmic Surgeon UK National Health Service, and various positions to senior executive level in market access consulting firms including United BioSource Corporation, Evidera and Market Access Solutions LLC, prior to launching Valid Insight. His education includes a first-class BSc in Biochemistry, degrees in Medicine and Surgery from Gonville and Caius College, Cambridge, and a postgraduate diploma in Ophthalmology.
Steve writes and speaks regularly on the challenges facing the global healthcare environment; he presents widely at conferences and expert panels, and has authored over 30 publications. His research interests span multiple therapy areas across drugs, devices and biotechnologies, including innovative medicines for rare diseases. He is a peer reviewer for several medical journals, Advisory Board Member at Pharma-IQ and the Global Pneumonia Prevention Coalition, and has been quoted in publications such as BioPharm Insight, Hospital Pharmacy Europe, and Reuters.
Raf De Wilde
Senior Executive Advisor
Raf De Wilde is Senior Executive Advisor at Valid Insight. He is a global expert in life science market access, having over 37 years’ experience in the pharmaceutical industry and over 27 years in global market access.
Raf became the head of International Marketing Services within Janssen Pharmaceutica (a Johnson & Johnson (J&J) company) in 1991, introducing Health Economics at J&J that year. Raf was Chairman of EPhMRA Primary Research and Methods Committee (1993-1995). He became VP of EPhMRA in 1994 and 1997 and President in 1995 and 1998.
In 1997, he joined Peter Lauper’s team that pioneered the ‘biosimilars’ concept and the first patient access schemes. Raf led a specialist oncology, real-world evidence and virology group between 2002 and 2004, where he created a centre of excellence for oncology pricing and specialised in biologics while leading the HEOR function at CENTOCOR. Raf was VP of Market Access at J&J leading teams working on oncology, cardiovascular and biotech products from 2004 to 2010.
Raf joined United Biosource Corporation (UBC) as Associate VP in early 2011 and stayed with Evidera until 2015, prior to joining Valid Insight in 2016. In his consulting career he has led over 100 global market access projects, including value strategies, price finding research, patient access schemes, negotiation tactics, tendering and contracting, WHO classification and naming strategies. He has moderated over 120 training workshops in Asia, Asia-Pacific, Europe, North America and Middle-East, and led the life sciences pricing training of the European Pricing Platform from 2011 to 2014.
Raf continues to teach the sessions on PROs and evidence-based medicine at the Master of Science in Pharmaceutical Medicine course of the University of Duisburg-Essen in Germany.
BA, MA, MSc, DPhil
Crispin Jenkinson is Senior Advisor at Valid Insight. He is Professor of Health Services Research, Director of the Health Services Research Unit at the Nuffield Department of Population Health, and a Senior Research Fellow of Harris Manchester College at the University of Oxford. He graduated from Bedford College (University of London) before coming to Oxford where he gained an MSc in Psychology and then undertook research on the psychological impact of long-term illness for a DPhil. His main research interests include patient reported outcomes (PROs) and health status measurement, the evaluation of patient experiences of medical care, and methodology. He has extensive experience of developing and validating outcome measures and, in collaboration with others, has conducted randomised controlled trials in which such instruments have been primary end-points. This work has led to the development of several internationally recognized PRO measures including the Parkinson’s Disease Questionnaire (PDQ), Amyotrophic Lateral Sclerosis Questionnaire (ALSAQ), and the Endometriosis Health Profile (EHP). He has written and edited many books as well as having authored over 210 peer reviewed publications.
Crispin helps our clients develop fit-for-purpose PRO and other health status instruments.
Carole Alison Chrvala
Carole Chrvala is Senior Advisor at Valid Insight. She has over 25 years’ experience as an epidemiologist and HEOR researcher. Her work spans collaborations with government health agencies, payers, academic institutions, pharmaceutical and medical device companies, medical education and communication organisations, and healthcare professional societies located in the US, UK, EU, and Israel. Carole is highly experienced in epidemiologic consulting, biostatistical support, strategic competitive analysis, medical intelligence, medical writing and publication planning services in diverse therapeutic areas including oncology, cardiovascular disease, diabetes mellitus, infectious diseases, musculoskeletal disorders, neurologic disorders, pain, psychiatric disorders, rare diseases, respiratory disorders, rheumatologic disorders, and women’s health.
Carole has developed and validated risk prediction models for various chronic and infectious diseases, analysed health care resource utilisation and economic burden, determined projections for the global epidemiologic burden of diverse health conditions, developed prospective and retrospective research studies to examine the impact of clinical interventions and developed statistical analysis plans for retrospective and prospective case-control studies and randomised clinical trials.
Carole was director of Cancer Prevention and Control for the Colorado Department of Public Health and Environment (CDPHE), before setting up her own independent company. She joined the US Food and Drug Administration as a Senior Scientist and later joined the National Academies of Science as a Senior Program Officer. She has written and presented on epidemiology, health economics and outcomes research, and diverse health topics to more than 75 professional audiences and organisations.
Senior Director, Head of Practice
Alison Kneen is Senior Director and Head of Practice. She has thirty-three years’ experience, within the NHS, the biotech and pharmaceutical industry, and in life science consulting; twenty-seven of those years were in market access. She was one of the inaugural members of the Astra Pharmaceuticals first-ever UK market access team back in 1992 and has specialised in market access strategy ever since.
Alison has provided strategic market access support to many pharmaceutical clients, from small biotech companies to large blue-chip pharmaceutical and technology organisations.
She specialises in launch excellence in specialist and rare diseases which is a key passion of hers which she holds to this day. It was while working with Novartis that Alison secured reimbursement for Glivec prior to it becoming commercially available for their first ever indication via a market access and public affairs engagement plan. This was the first high-cost orphan drug for rare disease which came under intense global scrutiny from payers. In her career, Alison has worked with AstraZeneca, Novartis, GSK and Baxalta, which recently merged with Shire in a period of time when they were launching many new chemical entities, and latterly for IMS Health, where Alison was Head of the Market Access Strategic Consulting team, prior to joining Valid Insight.
Having worked in both industry and consulting, Alison has guided many products and clients through majority of steps required for development and implementation of an effective market access strategy, including early value creation and launch excellence plans. Alison also has extensive experience with HTA submissions, working in partnership with clients to achieve EAMS & PIM designation, and development of patient access schemes. She understands the challenges and importance of achieving rapid commercialisation and has facilitated many strategy and negotiation workshops to assist clients with gaining market entry and market expansion of their products in numerous markets. Alison is also recognised as an industry expert on Irish market access and has advised and trained multiple companies on local reimbursement strategies.
In addition to having worked in most of the largest therapy areas, Alison has a wealth of experience in blood disorders, immunology, CNS and vaccines, and has an absolute passion for market access strategy.
Director, Value Communication
Tammy Wynne is Director of Value Communication. She has over ten years’ experience in global market access consultancy and value communications.
Prior to joining Valid Insight, Tammy held senior leadership positions at Covance Market Access and Medaxial for over 5 years. She also worked at Medicus International as a Senior Medical Writer.
Tammy specialises in supporting strategic secondary research, value communication consulting and medical/economic writing, having worked on a wide range of market access projects across numerous therapeutic areas and product profiles.
Projects have been proven to equip client teams for their communication challenges, enabling them to achieve/maintain market access, and have included: >100 value communication strategy/ message development engagements and slide decks, >50 presentation tools and economic models, dossiers and strategic/objection handling guides, plus designing and executing training/workshops.
Tammy has a first-class Degree in Biochemistry from the University of Nottingham.
Dip HE, MSc
James Wright is Associate Director at Valid Insight and has over twenty years’ experience in the healthcare industry and consulting. He joined Valid Insight after 13 years at QuintilesIMS.
James has provided market access support to most of the top 25 pharmaceutical companies and has extensive experience in HTA optimisation, evaluation of strategic pricing and market access implications for new launches, and product/portfolio lifecycle optimisation. James’ experience covers all major therapy areas, including rare and orphan disease, plus extensive work in biologics across established and emerging markets. James also specialises in clinical trial assessment, payer positioning, value and pricing strategy and lifecycle management.
James has an MSc in Health Economics and Pharmacoeconomics from Universitat Pompeu Fabra.
BSc (Hons.), MRes, PhD
Dominic Jones-Phillips is a Senior Consultant at Valid Insight. He has over a decade’s experience in consulting and industry.
He began his career as a research scientist at Syngenta CTL, and gained experience in healthcare and payer dynamics across the EMEA, US/Canada and Asia Pacific pricing and reimbursement environment through positions at DRG and Abacus International and Apex Healthcare Consulting, prior to joining Valid Insight.
Dominic has worked with pharmaceutical, biotech and medical device companies across multiple therapy areas and specialises in strategic pricing, reimbursement and payer launch strategy. He has also worked on and moderated multiple payer advisory boards, negotiation trainings and value challenge workshops, as well as actively participating in market access congresses.
Dominic has a BSc (Hons.) in Biochemistry and Master of Research (MRes) in Functional Genomics from the University of York, and a PhD in Experimental Rheumatology from the University of Leeds.
Please use the contact form if you have any questions about our services.
152 City Road
+44 (0) 20 3750 9833